Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $260000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 12.55% year-over-year to $260000.0, compared with a TTM value of $260000.0 through Sep 2025, up 12.55%, and an annual FY2025 reading of $260000.0, up 12.55% over the prior year.
  • Other Non-Current Liabilities was $260000.0 for Q3 2025 at Enanta Pharmaceuticals, up from $243000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $1.5 million in Q3 2021 and bottomed at $231000.0 in Q3 2024.
  • Average Other Non-Current Liabilities over 5 years is $697000.0, with a median of $520000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities plummeted 83.77% in 2024, then rose 12.55% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $520000.0 in 2021, then skyrocketed by 173.65% to $1.4 million in 2022, then crashed by 54.39% to $649000.0 in 2023, then tumbled by 63.79% to $235000.0 in 2024, then increased by 10.64% to $260000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ENTA at $260000.0 in Q3 2025, $243000.0 in Q1 2025, and $235000.0 in Q4 2024.